Movasin, tablets 15 mg 20 pcs

Meloxicam is a non-steroidal anti-inflammatory drug (NSAID) with analgesic, anti-inflammatory and antipyretic effects. The mechanism of action is associated with inhibition of prostaglandin synthesis as a result of selective inhibition of enzymatic activity of cyclooxygenase-2 (COX-2), involved in the biosynthesis of prostaglandins in the area of inflammation.

When administered in high doses, prolonged use and individual characteristics of the body, COX-2 selectivity decreases. Suppresses prostaglandin synthesis in the area of inflammation to a greater extent than in the gastric mucosa or kidneys, which is associated with relatively selective inhibition of COX-2.

It is less likely to cause gastrointestinal (GI) erosive-ulcerative disease. To a lesser extent, meloxicam acts on cyclooxygenase-1 (COX-1), which is involved in the synthesis of prostaglandins that protect the mucosa of the gastrointestinal tract and are involved in the regulation of blood flow in the kidneys.

Indications

symptomatic treatment of osteoarthritis;
symptomatic treatment of rheumatoid arthritis;
symptomatic treatment of ankylosing spondylitis (ankylosing spondylitis).

Pharmacological effect

Meloxicam is a non-steroidal anti-inflammatory drug (NSAID) with analgesic, anti-inflammatory and antipyretic effects. The mechanism of action is associated with inhibition of prostaglandin synthesis as a result of selective suppression of the enzymatic activity of cyclooxygenase-2 (COX-2), involved in the biosynthesis of prostaglandins in the area of ​​inflammation.

When prescribed in high doses, long-term use and individual characteristics of the body, selectivity for COX-2 decreases. Suppresses the synthesis of prostaglandins in the area of ​​inflammation to a greater extent than in the gastric mucosa or kidneys, which is associated with relatively selective inhibition of COX-2.

Less commonly causes erosive and ulcerative diseases of the gastrointestinal tract (GIT). To a lesser extent, meloxicam acts on cyclooxygenase-1 (COX-1), which is involved in the synthesis of prostaglandins that protect the gastrointestinal mucosa and are involved in the regulation of blood flow in the kidneys.

Special instructions

Caution should be exercised when using the drug Movasin in patients with a history of gastric and duodenal ulcers, as well as in patients on anticoagulant therapy. Such patients have an increased risk of erosive and ulcerative diseases of the gastrointestinal tract;
caution should be exercised and monitoring of renal function indicators when using the drug Movasin in elderly patients, patients with chronic heart failure (CHF) with symptoms of circulatory failure, in patients with cirrhosis of the liver, as well as in patients with hypovolemia as a result of surgical interventions;
in patients with a slight or moderate decrease in renal function (creatinine clearance more than 30 ml/min), no dosage adjustment is required;
Patients taking diuretics and meloxicam simultaneously should take sufficient fluids;
if allergic reactions occur during treatment (itching, skin rash, urticaria, photosensitivity), you must consult a doctor to decide whether to stop taking Movasin;
meloxicam, like other NSAIDs, can mask the symptoms of infectious diseases;
the use of meloxicam, like other drugs that block prostaglandin synthesis, can affect fertility and is therefore not recommended for women wishing to become pregnant.

Driving vehicles, servicing machines and mechanisms
The use of the drug Movasin can cause undesirable effects such as headaches, dizziness, and drowsiness, therefore, while taking the drug, you should avoid driving vehicles and servicing machines and mechanisms that require concentration.

Active ingredient

Meloxicam

Composition

1 tab.:

– meloxicam (based on 100% substance) 7.5 mg or 15 mg

Excipients:

povidone-12.6 thousand (low molecular weight medical polyvinylpyrrolidone 12600± 2700),

lactose monohydrate (milk sugar),

crospovidone (Kollidon CL, Kollidon CL-M),

potato starch,

talc,

magnesium stearate,

microcrystalline cellulose.

Pregnancy

It is recommended to consult a doctor before use.

Contraindications

hypersensitivity to meloxicam or excipients of the drug; the drug contains lactose, so patients with rare hereditary diseases such as galactose intolerance, lactase deficiency or glucose-galactose malabsorption should not take the drug;
condition after coronary artery bypass surgery;
uncompensated heart failure;
complete and incomplete combination of bronchial asthma, nasal polynosis and intolerance to acetylsalicylic acid and other NSAIDs;
erosive and ulcerative changes in the mucous membrane of the stomach or duodenum, active gastrointestinal bleeding;
inflammatory bowel diseases (ulcerative colitis, Crohn’s disease);
cerebrovascular bleeding or other bleeding;
severe liver failure or active liver disease;
chronic renal failure in patients not undergoing dialysis (creatinine clearance (CC) less than 30 ml/min), progressive kidney diseases, incl. confirmed hyperkalemia;
pregnancy, breastfeeding period;
children’s age up to 12 years.

With caution.
Coronary heart disease (CHD), cerebrovascular diseases, compensated heart failure, dyslipidemia/hyperlipidemia, diabetes mellitus, peripheral arterial disease, smoking, CC 30-60 ml/min.
Anamnestic data on the development of ulcerative lesions of the gastrointestinal tract, the presence of Helicobacter pуlori infection, old age, long-term use of NSAIDs, frequent alcohol consumption, severe somatic diseases, concomitant therapy with the following drugs:
– anticoagulants (for example, warfarin);
– antiplatelet agents (for example, acetylsalicylic acid, clopidogrel);
– oral glucocorticosteroids (GCS) (for example, prednisolone);
– selective serotonin reuptake inhibitors (for example, citalopram, fluoxetine, paroxetine, sertraline).
To reduce the risk of developing adverse events from the gastrointestinal tract, the minimum effective dose should be used for the shortest possible short course.

Side Effects

From the digestive system: more than 1% – dyspepsia, incl. nausea, vomiting, abdominal pain, constipation, flatulence, diarrhea; 0.1-1% – transient increase in the activity of “liver” transaminases, hyperbilirubinemia, belching, esophagitis, gastroduodenal ulcer, bleeding from the gastrointestinal tract (including hidden), stomatitis; less than 0.1% – gastrointestinal perforation, colitis, hepatitis, gastritis.

From the hematopoietic organs: more than 1% – anemia; 0.1-1% – change in blood formula, incl. leukopenia, thrombocytopenia.

From the skin: more than 1% – itching, skin rash; 0.1-1% – urticaria; less than 0.1% – photosensitivity, bullous rashes, erythema multiforme, incl. Stevens-Johnson syndrome, toxic epidermal necrolysis.

From the respiratory system: less than 0.1% – bronchospasm.

From the nervous system: more than 1% – dizziness, headache; 0.1-1% – vertigo, tinnitus, drowsiness; less than 0.1% – confusion, disorientation, emotional lability.

From the cardiovascular system (CVS): more than 1% – peripheral edema; 0.1-1% – increased blood pressure (BP), palpitations, “flushes” of blood to the skin of the face.

From the urinary system: 0.1-1% – hypercreatininemia and/or increased urea in the blood serum; less than 0.1% – acute renal failure; no connection with meloxicam has been established – interstitial nephritis, albuminuria, hematuria.

From the senses: less than 0.1% – conjunctivitis, visual impairment, incl. blurred vision.

Allergic reactions: less than 0.1% – angioedema, anaphylactoid/anaphylactic reactions.

Interaction

when used simultaneously with other NSAIDs (as well as with acetylsalicylic acid), the risk of erosive and ulcerative lesions and gastrointestinal bleeding increases;
with simultaneous use of Movasin with antihypertensive drugs, the effectiveness of the latter may decrease;
with simultaneous use with lithium preparations, the development of accumulation of lithium and an increase in its toxic effect is possible (monitoring the concentration of lithium in the blood is recommended);
with the simultaneous use of Movasin with methotrexate, the side effect of the latter on the hematopoietic system increases (the risk of anemia and leukopenia, periodic monitoring of a general blood test is indicated);
when used simultaneously with diuretics and cyclosporine, the risk of developing renal failure increases;
with simultaneous use of Movasin with intrauterine contraceptives, the effectiveness of the latter may decrease;
when used simultaneously with anticoagulants (heparin, ticlopidine, warfarin), as well as with thrombolytic drugs (streptokinase, fibrinolysin), the risk of bleeding increases (periodic monitoring of blood clotting parameters is necessary);
with simultaneous use of Movasin with cholestyramine, the elimination of the drug from the body is accelerated;
When used simultaneously with selective serotonin reuptake inhibitors, the risk of bleeding from the gastrointestinal tract increases.

Overdose

Symptoms: impaired consciousness, nausea, vomiting, epigastric pain, gastrointestinal bleeding, acute renal failure, liver failure, respiratory arrest, asystole.

Treatment: there is no specific antidote; In case of an overdose of the drug, gastric lavage, intake of activated carbon (within the next hour), and symptomatic therapy should be performed. Forced diuresis, alkalization of urine, hemodialysis are ineffective due to the high binding of the drug to blood proteins.

Storage conditions

In a dry place, protected from light, at a temperature not exceeding 25 °C

Shelf life

2 years

Manufacturer

Sintez, Russia